Company Interview / How this small cap plans to keep the growth going

Brian Ward from Aroa Biosurgery (ASX: ARX) shares insights into the company's FY25 results, highlighting revenue of $84.7 million and $4.2 million in normalised EBITDA. With a gross margin of 86% and $22 million in cash, Brian notes they are cash flow positive in H2, setting up for continued growth.

Brian discusses the success of their Myriad product, primarily used in treating large complex wounds. These include trauma and lower limb reconstruction, accounting for 75% of soft tissue reconstructions in hospitals. Most activity remains US-based, with plans for growth supported by global registrations.

He mentions Symphony, another product close to completing trials for diabetic and venous ulcers, with anticipated reimbursement by 2026. Challenges with US reimbursement processes have temporarily paused its rollout. US tariffs have a small impact, with an expected $1.5 million effect on $100 million in sales due to current arrangements.